Nanologica and Sterling Partner on Silica Production

News
Article

Nanologica AB has entered into a service agreement with CDMO Sterling Pharma Solutions for the large-scale production of silica particles.

Nanologica AB has entered into a service agreement with contract development and manufacturing organization (CDMO) Sterling Pharma Solutions for the large-scale production of silica particles. Nanologica specializes in the development and manufacture of silica for application in drug delivery and chromatography. Using Nanologica's technology, Sterling Pharma Solutions will produce large volumes of chromatography material needed to perform preparative chromatography.

“This new partnership [with Sterling Pharma Solutions] will allow us to scale production to completely different volumes than what is possible from our own site in Södertälje, Sweden. In practice, this means that our capacity increases from tens of kilograms to tens of tonnes,” Andreas Bhagwani, CEO of Nanologica, said in a press statement.

Nanologica will start manufacturing preparatory chromatography media, which is used in pharmaceutical manufacturing to "purify" peptides, specifically insulin. Significantly greater amounts of silica are used in preparative chromatography than in analytical chromatography, where Nanologica is active today.

Sterling Pharma Solutions, based in the North East of England, United Kingdom, is a manufacturer of active substances, materials, and products for customers in the pharmaceutical industry.

Source: Sterling Pharma Solutions

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Related Content